Inflammatory Biomarkers in the Assessment of Kidney Function Decline in Long COVID Syndrome Authors: Margherita Borriello, Roberta Ranieri, Annapaola Coppola, Patrizia Lombari, Riccardo Nevola, Aldo Marrone, Giuseppe Signoriello, Luigi Elio Adinolfi, Nicola Coppola, Diana Ingrosso, Flavia Maria Longo, Christian Di Maro, Carlo Maria Alfieri, Diego Ingrosso, Mariadelina Simeoni, Alessandra Perna Published: 2026 ABSTRACT AbstractIntroductionLong COVID (LC) is an inflammatory condition, affecting multiple organs, including kidneys. This study aims to identify a signature of inflammatory biomarkers that can predict, describe, and monitor kidney function decline in LC patients.MethodsA single-center observational study was carried out at the COVID Center of University of Campania “L. Vanvitelli.” Patients who survived the acute phase were invited for a follow-up visit at least 12 months after discharge. Based on the estimated glomerular filtration rate (eGFR), patients were categorized in three groups: group 1: eGFR >90 mL/min × 1.73 m2, group 2: eGFR 30–89 mL/min × 1.73 m2, and group 3: eGFR <30 mL/min × 1.73 m2. The multiplex ELLA platform was employed to quantify serum levels of inflammatory biomarkers including IL-6, IL-17, IL-10, IL-1β, PTX3, TNF-α, VCAM-1, ICAM-1, and E-selectin. Associations between each biomarker level and eGFR were analyzed.ResultsA decline in the eGFR at follow-up compared to that at admission was observed. IL-6 levels increased significantly as the eGFR decreased across the groups. IL-17, IL-10, and VCAM1 levels were markedly elevated in group 3.ConclusionsAccording to our results, IL-6, IL-17, IL-10, and VCAM1 constitute a biomarker signature associated with poorer renal prognosis in LC patients. The rise in IL-6 could drive an increase in IL-17, IL-10, and VCAM1, contributing to kidney function decline. These findings may help establish a clinical and laboratory framework to predict chronic kidney disease risk in LC. Furthermore, ELLA platform appears as a useful tool for inflammatory biomarker quantification in the clinical setting. Introduction Seven years after the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, there is still a significant number of people who survived but never fully recovered from the disease. Long COVID (LC) also named post-acute sequelae of COVID, is defined as “the continuation or development of new symptoms 3 months after an initial SARS-CoV-2 infection” [1]. More than 200 symptoms have been identified, with impact on various organ systems. Some progress has been made in the identification of various pathophysiological changes and risk factors and in the characterization of this disease’s complications. A list of common symptoms of LC, although not exhaustive, include tiredness or fatigue, difficulty in thinking and concentrating (often called “brain fog”), shortness of breath or difficulty in breathing, headache, dizziness on standing, fast-beating or pounding heart (known as heart palpitations), chest pain, cough, muscle pain, depression or anxiety, fever, and loss of taste and/or smell. LC is associated with damage to various organs, such as the heart, lungs, skin, brain, and kidneys (US Department of Health and Human Services, https://www.hhs.gov/civil-rights/for-providers/civil-rights-covid19/guidance-long-covid-disability/index.html-visited.16/01/2024) [2]. The cumulative global incidence of LC is around 400 million individuals, which is estimated to be endowed with an annual economic impact of approximately USD 1 trillion – equivalent to about 1% of global economy [3]. The ongoing burden of LC and related disability is therefore substantial and warrants increased attention by public health and medical communities [2, 4]. LC has been recognized as an inflammatory-based debilitating disease, complicated by multiorgan dysfunction [5]. Very recently, the study of the inflammatory pathophysiology of LC has shown the activation of the JAK/STAT pathway, as well as complement activation in LC syndrome [6]. It has been established that one of the most frequent long-term consequences of SARS-CoV-2 infection is kidney function decline, and eventually, chronic kidney disease (CKD) [7, 8]. CKD is a syndrome defined as alterations in kidney function and/or structure lasting more than 3 months characterized by the loss of nephrons and renal fibrosis [9]. CKD in turn is a health care problem, comparable to important noncommunicable diseases such as diabetes. About 10% of the world population is affected by CKD, and it is estimated to become the fifth cause of death by 2040 [10]. The gradual decline in kidney function leads to the accumulation of uremic solutes, with a negative effect on various organs, and particularly the cardiovascular system, leading to a lower quality of life, increased health care costs, and mortality [11]. To explain the high rate of cardiovascular disease in CKD, much attention has been paid to the nontraditional risk factors including uremic toxins retention, pro-inflammatory molecules increase, and endothelial dysfunction [12]. These considerations relative to kidney outcomes are particularly relevant in LC. In this respect, Bowe et al. reported that US veterans, who experienced LC, displayed an increased risk of various kidney outcomes, including a significant glomerular filtration rate (eGFR) decline [7]. Atiquzzaman and coworkers demonstrated that people with LC experienced a substantial eGFR decline within 1 year from the beginning of infection [8]. LC pathophysiology appears to be based on chronic inflammation [13]. Some studies analyzed the levels of various cytokines, in the attempt to identify involved cytokines and chemokines. Results from these studies were sometimes contradictory [4, 14–17]. These differences can be ascribed to the multitude of symptoms and organ dysfunction encompassed in LC, rendering arduous the possibility to develop a panel of biochemical markers able to define LC. To overcome these issues, it could be useful to explore the association between LC clinical manifestations (i.e., specific organ dysfunction) with a suitable biochemical profile, which is able to predict an increased risk of specific kidney outcomes. Materials and Methods Study Design A single-center prospective observational study was carried out at the COVID Center in collaboration with the Nephrology and Dialysis Unit within the University Hospital “L. Vanvitelli,” Naples (Italy). All patients with SARS-CoV-2 infection consecutively admitted between December 13, 2020 and May 13, 2021 and surviving the acute and post-acute phases were offered an outpatient follow-up visit at least 12 months after discharge. Data Collection and Sample Preparation The study was approved by the Ethics Committee of the University of Campania “L. Vanvitelli,” Naples (No. 10,877/2020; approval date: May 6, 2020). All procedures performed in this study were in accordance with the ethics standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethics standards. Informed consent was obtained from all participants enrolled in the study. To exclude a new SARS-CoV-2 infection at the follow-up visit, each patient underwent an antigenic nasopharyngeal swab. LC symptom burden at follow-up using a standard questionnaire regarding the persistence or onset of new symptoms since hospital discharge was assessed. In addition, patients underwent reevaluation of respiratory (via blood gas analysis, 6-minute walking test, basal and forced spirometry, and thoracic ultrasound) and cardiac (via electrocardiogram and trans-thoracic echocardiography) functions. Finally, blood samples were collected for each patient. Whole blood was collected in vacutainer with separator gel. After collection, samples were centrifuged at 1,500 g × 10 min, and the resulting serum was stored at −20°C until analysis. Renal function was assessed by the CKD-EPI formula (eGFR). According to eGFR, three statistically comparable groups were obtained. Specifically, group 1 contained patients with an eGFR >90 mL/min × 1.73 m2; group 2, patients with an eGFR 30–89 mL/min × 1.73 m2; and group 3, patients with an eGFR <30 mL/min × 1.73 m2. Biomarkers Choice and Quantification Several studies demonstrated an association between LC and the increase of various circulating inflammatory mediators. Among them, interleukin-6 (IL-6), IL-17, IL-10, IL-1b, pentraxin-3 (PTX3), and tumor necrosis factor-α (TNF-α) [4, 14–18] were described. Moreover, LC is characterized by an increase in some biomarkers of endothelial dysfunction, including vascular cell adhesion molecule 1 (VCAM-1), intra cellular adhesion molecule 1 (ICAM-1), and E-selectin [19, 20], realizing a so-called “endotheliopathy.” All the above-mentioned biochemical markers were quantified in serum samples of the enrolled population by semiautomated ELISA – Simple Plex ELLA platform, equipped with Simple Plex Cartridge Kit for 32 samples (ELLA Simple Plex, Bio-Techne, Minneapolis, MN, USA). Two array kits were used, the first containing IL-10, IL-17A, IL-1b/IL-1F2, IL-6 2nd gen, TNF-α 2nd gen, TSG-14/pentraxin-3 (SPCKE-PS-009155), and the second array kit containing ICAM-1, VCAM-1, E-selectin (SPCKC-PS-002493). ELLA calibration and control check were performed using the in-cartridge factory standard curve, and serum samples were diluted and centrifugated as indicated in the manufacturer instructions (https://www.bio-techne.com/reagents/simplepleximmnasays?gad_source=1&gclid=CjwKCAjw17qvBhBrEiwA1rU9w3Z60_8fOsI3pzL2GO3OFfXa0cm2CdiuDV3WIZ-vBgUNMaPMiQ5yuBoC2U0QAvD_BwE&gclsrc=aw.ds). Statistical Analysis Statistical variables were characterized using relevant summary and variance measures. Group comparisons were conducted utilizing suitable parametric and nonparametric statistical tests. Differences in mean age across eGFR groups were assessed using one-way ANOVA, and a test for linear trend was evaluated using linear regression with the eGFR group entered as an ordinal variable. Multiple-group comparisons of quantitative variables were accomplished through one-way ANOVA. In case of significant ANOVA, Bonferroni’s test was used as a post hoc statistical test to compare multiple group means. Qualitative variables were analyzed using the chi-square test and Fisher’s exact test. Wilcoxon signed rank test was used to compare and analyze eGFR in admission and at the follow-up. Statistical significance was established at the p < 0.05 significance level. The software STATA/SE version 18 for Windows was used. Results Of the 208 patients admitted to the COVID Center, 170 survived at least 12 months after hospital discharge. Of these, only 78 patients attended the follow-up visit and were enrolled in the study. Among the 78 patients enrolled, it could be interesting to highlight that 35 of them (i.e., 44.87%) needed noninvasive ventilation support during COVID acute phase. Patients were reevaluated on an outpatient basis from 17 March to July 14, 2022. Anthropometric and 1-year follow-up clinical variables of the enrolled population are summarized in Table 1. Table 1.Characteristics of the enrolled population regarding the clinical evaluation of the reported disease after 1 year from the admission at the “L. Vanvitelli” COVID CenterAge, mean (SD), years​61.7 (12.8)Sex, n (%)F22 (28%)M58 (72%)Smoking, n (%)No43 (51.28%)Yes15 (19.23%)Ex-smoker20 (25.64%)Diabetes mellitus type 2, n (%)No59 (75.64%)Yes19 (24.35%)Hypertension, n (%)No37 (47.43%)Yes41 (52.56%)Obesity, n (%)No62 (79.48%)Yes16 (20.51%)Liver disease, n (%)No69 (88.46%)Yes9 (11.53%)Chronic obstructive pulmonary disease, n (%)No70 (89.74%)Yes8 (10.25%)Neoplasia, n (%)No75 (96.15%)Yes3 (3.84%)Pacemaker, n (%)No75 (96.15%)Yes3 (3.84%)Atrial fibrillation, n (%)No73 (93.58%)Yes5 (6.41%)Ischemic heart disease, n (%)No70 (89.74%)Yes8 (10.25%)Heart failure, n (%)No77 (99%)Yes1 (1%)Valvulopathy, n (%)No75 (96.15%)Yes3 (3.84%) Characteristics of the enrolled population regarding the clinical evaluation of the reported disease after 1 year from the admission at the “L. Vanvitelli” COVID Center LC-Associated Symptoms The presence of several LC symptoms was evaluated, and the results are shown in Table 2. The results highlighted that the symptoms mainly correlated with LC, in the analyzed cohort, were headache, dyspnea, joint pain, sleep disturbance, memory deficiency, myalgia, chest pain, cough, palpitation, depression, and anxiety. Table 2.LC associated symptomsHeadache, n (%)No63 (81.81%)Yes10 (12.98%)Excluded4 (5.19%)Constipation, n (%)No58 (75.32%)Yes11(13,75%)Pre-Cov Excluded11 (13.75%)Dyspnea, n (%)No34 (45.33%)Yes39 (50%)Excluded5 (6.66%)Joint pain, n (%)No39 (54.92%)Yes23 (45.07%)Excluded9 (12.67%)Palpitation, n (%)No52 (72.22%)Yes12 (16.66%)Excluded8 (11.11%)Sleep alteration, n (%)No40 (52.63%)Yes32 (44.73%)Excluded4 (5.2%)Mnesic deficiency, n (%)No36 (48%)Yes34 (45.33%)Excluded5 (6.6%)Skin rashes, n (%)No69 (90.78%)Yes3 (3.94%)Excluded4 (5.2%)Diarrhea, n (%)No72 (92.23%)Yes4 (7.69%)Excluded2 (2.5%)Myalgia, n (%)No38 (50%)Yes34 (44.73%)Excluded4 (5.2%)Chest pain, n (%)No55 (74.32%)Yes23 (29.11%)Excluded1 (1.3%)Cough, n (%)No55 (72.36%)Yes17 (22.36%)Excluded4 (5.2%)Depression, n (%)No44 (61.11%)Yes28 (36.84%)Excluded4 (5%)Anxiety, n (%)No45 (62.5%)Yes19 (26.38%)Excluded8 (11.12%)The symptoms were analyzed by a questionnaire submitted to the patients at the follow-up control. “Excluded” refers to patients excluded in the statistical analysis due to the presence of the symptom before SARS-CoV-2 infection. LC associated symptoms The symptoms were analyzed by a questionnaire submitted to the patients at the follow-up control. “Excluded” refers to patients excluded in the statistical analysis due to the presence of the symptom before SARS-CoV-2 infection. Distribution of Inflammatory and Endothelial Damage Biomarkers Based on eGFR in LC A panel of biochemical markers were selected and quantified in the enrolled patients as described in the Materials and Methods section. In Table 3, the median and the interquartile range (IQR) for each biomarker are reported. The stratification of the population in three comparable groups was based on renal function assessed by the CKD-EPI formula. In particular, we referred to KDIGO guidelines [21]. To create statistically comparable eGFR groups, patient from CKD stages 3a, 3b, 4, and 5 were merged, obtaining three eGFR classes (Table 4), as described above. Anthropometric variables in the comparative groups are analyzed in Table 4. As expected, eGFR decreased with age increase, and this relation was statistically significant (p < 0.001) (Table 4). Comparing the eGFR value at admission (i.e., when the patient reached our COVID Center) with eGFR at follow-up (i.e., when LC was diagnosed), a significant reduction in eGFR value was found (p = 0.0001) (Fig. 1; Table 5), indicating that LC is characterized by a reduction in kidney function. Specifically, analysis showed a significant reduction of eGFR during LC in group 2 (p = 0.0001) (Table 5). These results are in line with those showed by others, as mentioned before [8, 13]. Table 3.Median and the interquartile range (IQR) are reported for the quantified biomarkerBiomarkerMedian (IQR)IL-1b0.2 (0.1, 0.4)IL-101.23 (0.9, 1.7)IL-17A0.4 (0.0, 1.3)IL-6 2nd gen.1.7 (1.1, 2.8)ICAM-10.276 (0.118, 0.36)PTX-3832.0 (549.0, 1,427.0)E-selectin0.236 (0.122, 0.355)VCAM-10.49 (0.20, 0.642)TNF-α 2nd gen.7.8 (5.9, 11.5)Concentrations are expressed in pg/mL, except for ICAM-1, VCAM-1, and E-selectin, which are presented in μg/mL. Median and the interquartile range (IQR) are reported for the quantified biomarker Concentrations are expressed in pg/mL, except for ICAM-1, VCAM-1, and E-selectin, which are presented in μg/mL. Table 4.Age and sex association with each eGFR groupFactor​eGFR group 1eGFR group 2eGFR group 3 p value N ​17419​Age, mean (SD), years​51.6 (11.8)63.0 (12.7)72.8 (8.3) <0.001 Sex, n (%)F4 (24%)10 (24%)3 (33%)​M13 (76%)31 (76%)6 (67%)​ Age and sex association with each eGFR group Comparison between overall eGFR value at admission (i.e., when the patient reached the COVID Center) and eGFR at follow-up (i.e., when LC was diagnosed). See the “Materials and Methods” section for further details. Table 5.Comparison between the eGFR value in admission (eGFR-admit) with eGFR at follow-up (eGFR-LC)Group N eGFR-admiteGFR-LCMean difference95% Cl [22] p valueeGFR group 11799.32100.99−1.67−0.357 to 8.250.523eGFR group 24088.6175.4713.147.89 to 18.38 0.0001 eGFR group 3952.6741.5311.14−7.19 to 29.470.333Overall6785.9076.909.084.33 to 13.8 0.0001 The bold values are statistically significant. Comparison between the eGFR value in admission (eGFR-admit) with eGFR at follow-up (eGFR-LC) The bold values are statistically significant. The median concentrations of inflammatory biomarkers measured at follow-up are shown in Figure 2 and Table 6. Cytokine IL-6, increasing levels of which is known to be associated with cardiovascular events [23] especially in CKD [22, 23], significantly increased during LC, as the eGFR decreased. This increase is significantly present in group 2, and it doubles in group 3 (3 vs. 1: p = 0.008, 3 vs. 2: p = 0.001, Table 6). Cytokines IL-17 and IL-10 significantly increased only in group 3, as shown in Figure 2 and Table 6. On the other hand, no significant differences were found for PTX-3, IL-1β, and TNF-α in all compared eGFR groups (Table 6). Distribution of IL-6 (a), IL-17 (b), and IL-10 (c) cytokine concentration for each eGFR group. The concentration is expressed in pg/mL. Statistical significance among groups was determined using one-way ANOVA test (see the “Materials and Methods” section). Table 6.Median and interquartile range (IQR) for the quantified biomarker, for each eGFR stage considered at the follow-up visit, and relative statistical analysis (see the “Materials and Methods” section)​eGFR group 1eGFR group 2eGFR group 3 p valuePTX3, median (IQR)1.0 (0.6, 1.3)0.7 (0.5, 1.4)0.8 (0.6, 1.2)0.80IL-1b, median (IQR)0.2 (0.1, 0.4)0.2 (0.1, 0.4)0.2 (0.1, 0.3)0.69IL-10, median (IQR)1.2 (0.9, 1.6)1.2 (0.9, 1.6)1.9 (1.4, 2.6) 0.007 IL-10 (Bonferroni’s test)3 vs. 2: p = 0.006IL-17, median (IQR)0.4 (0.1, 0.9)0.4 (0.0, 1.2)1.5 (0.6, 2.6) 0.0264 IL-17 (Bonferroni’s test)3 vs. 1: p = 0.01183 vs. 2: p = 0.032IL6, median (IQR)1.4 (0.9, 2.0)1.7 (1.2, 2.6)2.9 (2.2, 3.2) 0.032 3 vs. 1: p = 0.008IL6, (Bonferroni’s test)​​3 vs. 2: p = 0.001​TNF-α_1, median (IQR)7.9 (6.1, 13.0)7.2 (5.4, 10.0)11.0 (5.7, 12.2)0.36E-selectin, median (IQR)0.23 (0.085, 0.362)0.25 (0.132, 0.35)0.185 (0.126, 0.362)0.93VCAM-1, median (IQR)0.475 (0.190, 0.6)0.448 (0.194, 0.61)0.73 (0.633, 1,1) 0.021 VCAM-1 (Bonferroni’s test)​​3 vs. 2: p = 0.001​3 vs. 1: p = 0.006ICAM-1, median (IQR)0.230 (0.087, 0.352)0.276 (0.117, 0.342)0.309 (0.181, 0.39)0.60The biomarkers’ concentration is expressed in pg/mL, except for ICAM-1, VCAM-1, and E-selectin (μg/mL).The bold values are statistically significant. Median and interquartile range (IQR) for the quantified biomarker, for each eGFR stage considered at the follow-up visit, and relative statistical analysis (see the “Materials and Methods” section) The biomarkers’ concentration is expressed in pg/mL, except for ICAM-1, VCAM-1, and E-selectin (μg/mL). The bold values are statistically significant. To evaluate endothelial damage, VCAM-1, ICAM-1, and E-selectin were quantitated. Among these, only VCAM-1 resulted to be significantly increased in group 3 (Table 6; Fig. 3). Although ICAM-1 and E-selectin did not differ among the analyzed groups, concentrations found in LC patients enrolled in this study were increased and overlap with those reported in other “endotheliopathy” studies, including LC [23, 24]. a–c Distribution of biomarkers of endothelial damage for each eGFR group analyzed. The biomarker concentration is expressed in μg/mL. Statistical significance among groups was determined using one-way ANOVA test (see the “Materials and Methods” section). Discussion The aim of this study was to investigate renal function decline in LC by identifying a panel of inflammatory mediators that may serve as a diagnostic and prognostic biomarker signature. Kidney complications may persist after COVID-19 recovery, but their long-term impact remains unclear [25]. In our cohort, results showed that LC-related symptoms mainly were headache, dyspnea, joint pain, sleep disturbance, memory deficiency, myalgia, chest pain, cough, palpitation, depression, and anxiety. With respect to kidney function, eGFR of enrolled patients was significantly reduced at 1-year follow-up with respect to eGFR registered during SARS-CoV-2 infection, indicating that LC is significantly associated with an increased CKD risk. In particular, group 2 (eGFR group 2: patients with an eGFR 60–89 mL/min x 1.73 m2) is significantly affected in our cohort, while a reduction of eGFR at follow-up in group 3 was not statistically significant (perhaps due to the low number of enrolled patients). This is in line with results obtained from Bowe et al. in US veterans [6, 7] and Atiquzzaman in a Canadian cohort [7]. It is worth noting that the mean age of the groups, as expected, was significantly reduced as eGFR decreased. In light of this, older age can be considered a potential contributing factor in the association between CKD and LC. This hypothesis is in line with the work by Bowe et al. [7] and with Finamore and coworkers [26], who found that aging influences both the likelihood of developing LC and the recovery process, due to age-related physiological changes, immune system alterations, and the presence of comorbidities. Our results could indicate that CKD renders patients more susceptible to LC complications. This hypothesis is in line with Yende and Parikh [27], who defined “bidirectional” relationship between COVID-19 and CKD. Furthermore, they emphasized that kidney disease progression after COVID-19 is likely multifactorial and might be driven by inflammation, tubular injury, or maladaptive repair, among other pathways. Indeed, the inverse relation between the rise of some pro-inflammatory mediators and eGFR decline is known [28, 29]. Novel kidney-specific plasma and urine biomarkers might help predict which patients are at highest risk of CKD after COVID-19 hospitalization. In this view, we tried to explore the possibility of identifying a relationship between some inflammatory biomarkers and eGFR decline in LC. Our results showed that IL-6 levels were significantly higher in group 2 and even more elevated in group 3. This pattern suggests that increased IL-6 concentrations are associated with worsening renal function and may precede alterations in other cytokines. The pathogenetic role of IL-6 in adverse cardiovascular events especially in CKD is well known [22, 23]. The rise in IL-6 is known to be related to eGFR decline; furthermore, IL-6 is classified as middle uremic toxin [29]. In uremic patients, IL-6 is linked to postoperative atrial fibrillation through a signal transducer and activator of transcription 3 (STAT3)-driven ryanodine receptor-2 calcium leak [30, 31]. Also, IL-6 accumulates during uremia and contributes to the high levels of fibroblast growth factor-23 (FGF23) observed in CKD [30, 32]. For this reason, there is growing interest in using IL-6 inhibitors to reduce cardiovascular risk in patients with CKD [23]. Taken together with existing evidence, our findings suggest that IL-6 may represent a biomarker associated with cardiovascular risk and renal dysfunction in LC. However, causality cannot be inferred from the present data, and further mechanistic studies are required to clarify its role. All these findings appear even more important, considering that cardiovascular disease is the major cause of death in CKD patients [33]. In addition, we found a significant increase in cytokines IL-17A and IL-10 only in group 3, the one with the worst eGFR. IL-17A is the best-known member of the IL-17 cytokines family. Although crucial in protecting the host from invasion by many types of pathogens, IL-17A is involved in chronic inflammation in various diseases [34]. Moreover, recent studies suggest a more complex role of IL-17 in kidney-associated diseases [32, 33] and also in LC [16]. On the other hand, IL-10 has been implicated in various inflammatory diseases such as kidney disease, rheumatoid arthritis, osteoarthritis, and cancer, by regulating inflammatory factors and immune responses. Previous studies revealed that specific IL-10 knockout upregulates proinflammatory factors in mice when renal function is damaged [35]. Corrèa and coworkers found that IL-10, together with phosphate, were higher in hemodialysis patients with LC (eGFR <15 mL/min × 1.73 m2). This may indicate that both IL-10 and phosphate may predict LC risk in this group of patients [36]. This evidence underpins the results of the present study, suggesting that the triad IL-6/IL-17/IL-10, taken together, may represent a possible signature for predicting kidney dysfunction in LC. In this regard, further studies should address this hypothesis. Regarding the biomarkers associated with endothelial damage evaluated in this work, only VCAM-1 was found significantly increased in group 3. Nevertheless, all the biomarkers of endothelial damage were found to be in a pathological concentration range, which could be ascribed to LC [19, 20, 37]. We can hypothesize, indeed, that all the analyzed markers of “endotheliopathy” were increased due to LC, but only VCAM-1 appears to be associated with kidney function decline. It could be possible to hypothesize that the concomitant increase of IL-17, IL-10, and VCAM-1 may represent a biochemical signature for an advanced kidney disfunction, predicting a worse prognosis in LC. The main limitation of the present study is the relatively small sample size and the imbalance in the sex distribution of the enrolled patients. Indeed, the majority of them were male, and this could represent a bias regarding both CKD severity and COVID-19 symptoms and may limit the generalizability of our findings to the broader population. In addition, the number of patients included in group 3 was relatively small. This limited sample size reduces the statistical power of the analysis and may partly explain why some observed trends did not reach statistical significance. Consequently, the results related to this subgroup should be interpreted as exploratory. It is worth noting that of the 208 patients admitted to our COVID Center, 170 survived at least 12 months after hospital discharge. Of these, only 78 patients attended the follow-up visit and were enrolled in the study. Moreover, the present study lacked a control group without LC. Conclusions Several studies highlight the critical importance of kidney function in the follow-up of patients who were infected by COVID-19. The present study assessed LC along with kidney function and a panel of biochemical markers associated to LC. We propose that IL-6/IL-17/IL-10, together with VCAM-1, represent a possible biomarker signature associated with reduced eGFR in LC. This hypothesis should be addressed with a larger cohort of patients using a longer follow-up and a control group of eGFR-stratified CKD patients without LC. Because various institutions define recommendations for a uniform management of LC, that require a multidisciplinary approach, the results obtained in the present study could be used to define a clinical and laboratory set of markers of LC to predict CKD risk. Moreover, we propose ELLA platform as a useful, low-cost, and reliable diagnostic tool to be used in this specific clinical setting. Statement of Ethics This study was performed in accordance with the Declaration of Helsinki. This human study was approved by the Ethics Committee of the University of Campania “L. Vanvitelli”; approval no. 10877/2020, approval date: May 6, 2020. All adult participants provided written informed consent to participate in this study. Conflict of Interest Statement Mariadelina Simeoni and Alessandra Perna were members of the journal’s Editorial Board at the time of submission. The other authors have no conflicts of interest to declare. Funding Sources This study was supported by Asse I “Ricerca e Innovazione,” Azione 1.3.1 – PON Campania FESR 2014/2020, CUP B63C22001240002 and partially supported by EUTox, European Uremic Toxins work group. Both funding organizations supported this research line and manuscript conception. Author Contributions Borriello, Perna, and Ingrosso Diego: conceptualization of the study. Nevola, Marrone, Adinolfi, and Coppola N: population enrollment and clinical evaluation; Ranieri, Simeoni, Alfieri, and Perna: nephrological evaluation. Longo: long COVID assessment (questionnaire administration). Borriello, Coppola AP, and Lombari: quantification of biochemical parameters. Signoriello and Ingrosso Diana: statistical analysis. Borriello and Nevola: writing – original draft preparation. Borriello, Coppola AP, Coppola N, Perna, Ingrosso Diego, Simeoni, and Di Maro: writing – review and editing.